Eurofins Scientific SE · EURONEXT:ERF
Eurofins Scientific — H1 2021 Earnings Presentation
29 slides from Eurofins Scientific's earnings presentation, Aug 5, 2021
Slide 1: H1 2021 Results Presentation
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on
Slide 3: Agenda
Agenda I. Introduction and highlights II. Financial review III. Operational review IV. Sustainability V. Outlook 3
Slide 4: I. Introduction and highlights
I. Introduction and highlights 4
Slide 5: Our Vision & Purpose: Testing for Life
Our Vision & Purpose: Testing for Life We aim to have a positive impact on LIFE, HEALTH and the ENVIRONMENT. 5
Slide 6: Key financial highlights H1 2021
Key financial highlights H1 2021 Revenue, EUR m Adjusted1 EBITDA2, EUR m Adjusted1 EBITDA2 Margin 3,272 30.8% +41% 1,008 +960bps 2,323 +104% 21.2% 493 H1 2020 H1 2021 H1 2020 H1 2021 H1 2020 H1 2021 Free Cash Flow to Firm3, EUR m Net debt/EBITDA4 Adjusted1 EPS5 489 2.5x 3.05 +55% 315 -1.5x +196% 1.0
Slide 7: Key operational highlights (1/2)
Key operational highlights (1/2) • Record H1 on revenues, profits and cash generation, continuing the positive trends seen in Q1 2021 • Strong performance of Core Business1 with rapidly accelerating, strong growth across business lines: o H1 2021: 17% organic growth2 o Q2 2021: 25% organic growth3 o
Slide 8: Organic revenue growth outperforms TIC industry peers
Even excluding COVID-19 clinical testing and reagents, Eurofins organic revenue growth continues to significantly outperform TIC industry peers H1 2020 H1 2021 H1 2021 vs. H1 2019² CAGR H1 2019 – 2021 20% 15% 1 3 10% 1 5% 3 3 0% 1 -5% -10% 3 Average TICS ex ERF 3 -15% CONFIDENTIAL AND PROPRIETARY -
Slide 9: Fastest growing TIC company, leader of an industry with attractive organic growth
Fastest growing TIC company which became the leader of an industry with attractive and resilient organic growth • Market Structural growth: est. ~1.5-2.0x Gross Domestic Product growth, globalisation, urbanisation, increasing need and demand for a healthier life and safer environment. Testing is the
Slide 10: Key operational highlights (2/2)
Key operational highlights (2/2) • Alongside the Core Business, the Group remains equally agile, committed and innovative to fight the pandemic • Significant contribution from COVID-19 related activities and important milestones reached in H1 2021: o Revenue contribution close to EUR 750m o 25+ mill
Slide 11: II. Financial review
II. Financial review CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 11
Slide 12: Record H1 results
Record H1 results Half Year 2021 Half Year 2020 Key Highlights +/- Δ +/- Δ • Record first six months, with strong Adjusted1 SDIs2 Reported Adjusted1 SDIs2 Reported Adjusted Reported growth of revenues (EUR 3,272m, Results Results Results Results Results Results +41% vs H1 2020) thanks to strong grow
Slide 13: Strong growth of revenues resulting in record semester
Strong growth of revenues resulting in record semester (EUR m) Key Highlights • Strong growth of revenues (+41% year-on-year, +43% organically) despite negative FX headwind of -3.3% • Strong organic growth of Core Business despite continued impact of lockdowns on some of our businesses thanks to: o
Slide 14: Strong cash flow performance in H1 2021
Strong cash flow performance in H1 2021 H1 2021 H1 2020 Δ% EUR m EUR m Key Highlights Change in net working capital1 -128 13 -1,054% • Strong cash flow generation, with Free Cash Flow to the Firm of EUR 489m (+55% vs Net cash provided by operating activities 709 445 +59% H1 2020), which coupled with
Slide 15: Controlled Net Working Capital use
Controlled Net Working Capital use Net working capital as a % of revenues Key Highlights 6.4% 6.6% • Net working capital back to 2019 mid-year levels, at 6.6% of revenues, as temporary postponements of social charges and tax payments put 5.3% in place by some governments in 2020 reversed in 2021 • D
Slide 16: Very solid liquidity position and significant reduction in leverage
Very solid liquidity position and significant reduction in leverage Leverage1 Debt maturity profile (EUR m) Key Highlights 800 Hybrid (1st call) Schuldschein Eurobond • Reduction of close to EUR 500m in corporate senior gross debt following successful refinancing exercises 700 • Capital management,
Slide 17: III. Operational review
III. Operational review CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 17
Slide 18: Our Core Business confirmed to be highly resilient
Our Core Business confirmed to be highly resilient • Core Business continued to perform very well with strong growth across business lines and geographies despite some continued impact of COVID related lockdowns and restrictions • Strong growth comes in part from faster recovery than expected at the
Slide 19: Transplant Genomics has grown its offering very strongly despite COVID-19
Transplant Genomics has grown its offering very strongly despite COVID-19 Quarterly revenues since acquisition, excluding COVID-19 Key Highlights related activities • Range of non-invasive molecular diagnostics tests has grown strongly since acquisition of TGI, particularly related to TruGraf®, its
Slide 20: Eurofins at the forefront of innovation with new COVID-19 developments
Eurofins at the forefront of innovation with new COVID-19 related developments • Two important milestones reached: o 25m+ COVID-19 PCR tests completed since the start of the pandemic o 125,000+ SARS-CoV-2 samples from 23 countries sequenced since its press release on 28th December 2020 announcing th
Slide 21: SAFER@WORK update
SAFER@WORK™ update • Through its SAFER@WORK™ programmes, Eurofins continues to help businesses maintain or re-start operations and to enable safe and secure travel and leisure • Over 3,250 SAFER@WORK™ contracts signed or in final stages across 36 countries (as of June 2021) • Eurofins developed a br
Slide 22: Sustainability remains at the heart of Eurofins' activities
Sustainability remains at the heart of Eurofins’ activities In H1 2021 the Group continued to embed best practices and make further progress on all three dimensions of ESG: • Established Sustainability and Corporate Governance Committee at Board level to demonstrate focus and commitment on these imp
Slide 23: V. Outlook
V. Outlook CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 23
Slide 24: Outlook: 2021 objectives upgraded
Outlook: 2021 objectives upgraded. 2022 and 2023 objectives excluding Covid unchanged for now We upgrade 2021 objectives by 13% for revenues and by 36% for EBITDA (all at average H1 2021 exchange rates). FY 2022 and FY 2023 remain unchanged at this time as the duration and magnitude of the COVID-19
Slide 25: Conclusions
Conclusions • Record six months thanks to strong growth of Core Business and sustained revenues from COVID-19 testing & reagents • Strong operational performance in H1 2021 o Core Business organic growth sets records in Q2 2021 at +25% year-on-year, +17% in H1 2021 and +13% vs pre-pandemic H1 2019 o
Slide 26: Q&A
Q&A CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 26
Slide 27: Appendix
Appendix CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 27
Slide 28: Segment performance
Segment performance Key Highlights Δ in Rep. Reported Revenues Δ in Reported Δ in Rep. • Rapid growth in Europe with revenues up 57% to EBITDA EBITDA Segment H1 2021 Revenues EBITDA H1 2021 EBITDA EUR 2,005m vs H1 2020, partly due to higher COVID vs H1 2020 margin EUR m vs H1 2020 EUR m margin relat
Slide 29: Definitions / Alternative Performance Measures (APMs)
Definitions / Alternative Performance Measures (APMs) Eurofins is providing in the consolidated financial statements certain alternative performance measures (non-IFRS information). APMs used in the Consolidated Income Statement Adjusted results – reflect the ongoing performance of the mature and re